Carcinoembryonic Antigen Market Report, Analysis, Size, Share, Growth, Trends and Forecast 2030
Carcinoembryonic
Antigen Market Highlights
Carcinoembryonic
antigen (CEA) is a group of glycoproteins which are produced during the Fetal
developmental stages by gastrointestinal tissues. CEA is responsible for cell
adhesion. Healthy adults do not have CEA concentrations. However, smoking, and
certain medical conditions such as colorectal cancer, breast cancer etc. can
mark the presence of CEA in the body. Thus, carcinoembryonic antigen market based
diagnostic assays are used for the detection of such cancers and to check the
treatment efficiency during the therapeutic period by a physician.
The Carcinoembryonic Antigen Market
is projected to reach USD 2,934.5 Million by 2030 at 15.2% CAGR during the
forecast period 2022-2030.
In
2017, studies of the NCBI suggested that the global burden of colorectal cancer
will increase by 60%, leading to 2.2 million new cancer cases and 1.1 million
deaths by 2030. This will increase the colorectal cancer diagnostic demands,
thereby propelling the market growth.
Increasing
prevalence of cancer, rising healthcare expenditures, and developing diagnostic
technologies will boost the global market during the forecast period. However,
risk of infection and hematoma, lack of awareness and medical services in the
developing countries will restrain the market growth during the assessment
period.
Market
Players
Carcinoembryonic
antigen market players profiled in the report are Lee BioSolutions, F.
Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated., Correlogic Systems,
Inc, Genway Biotech, Inc., Abbott., RayBiotech, Inc., Abcam plc., Biocare
Medical, LLC, and Biocare Medical, LLC.
Segmentation
The
global carcinoembryonic antigen market has been segmented based on application,
sampling, and end user.
Based
on application, the market has been segmented into colorectal, pancreatic,
breast, lung cancer, and others.
Based
on sampling, the market has been segmented into antecubital, peritoneal,
pleural, cerebrospinal, and others.
Based
on the end users, the market has been segmented into hospitals, diagnostic centres,
research centres, and others.
Regional
Analysis
The
Americas account for the largest share in the carcinoembryonic antigen market.
The Americas mainly include countries like the U.S. and Canada. Increasing
prevalence of cancer and high healthcare expenditures within the region will
boost the market growth over the assessment period.
Europe
is the second highest revenue generating region in the global carcinoembryonic antigen market report. Increasing prevalence of cancer, fast adoption of
new technologies and presence of developed countries like Germany and U.K
within the region will boost the market growth during the forecasted period.
Because
of the developing medical infrastructure, rising healthcare expenditure, and
increasing government initiatives, Asia Pacific region is expected to grow the
fastest.
The
Middle East & Africa is expected to grow slower than the global average.
The Middle Eastern countries, for instance, UAE and Saudi Arabia dominates the
market due to high income and the government support to improve public health.
Taste
the market data and market information presented through more than 50 market
data tables and figures spread over 80 pages of the project report. Avail the
in-depth table of content (TOC) & market synopsis on “Global Carcinoembryonic
Antigen Market” Research Report – Forecast till 2023.
About Market
Research Future:
At Market Research
Future (MRFR), we enable our customers to unravel the complexity of various
industries through our Cooked Research Report (CRR), Half-Cooked Research
Reports (HCRR), & Consulting Services. MRFR team have supreme objective to
provide the optimum quality market research and intelligence services to our
clients.
Contact us:
Market Research
Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,
5Th Floor,
New York, New York
10013
United States of
America
+1 628 258 0071
Email: sales@marketresearchfuture.com
Comments
Post a Comment